Aqueous extract of dioscorea opposita thunb. normalizes the hypertension in 2K1C hypertensive rats

BMC Complementary and Alternative Medicine

Anake Kijjoa³  Dolkun Mamut²  Zulpiya Osman⁵  Parida Hoxur⁴  Sajida Abdureyim¹  Raziya Amat⁵  Nurmuhammat Amat⁵ 

[1] First Affiliated Hospital, Xinjiang Medical University, 830011 Urumqi, Xinjiang, PR China;Salamat Biotechnology Co., Ltd, Urumqi, Xinjiang 830011 PR China;ICBAS-Instituto de Ciências Biomédicas de Abel Salazar and CIIMAR, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal;Traditional Chinese Medicine Hospital, Xinjiang Medical University, 830011 Urumqi, Xinjiang, PR China;Traditional Uighur Medicine Institute, Xinjiang Medical University, 830011 Urumqi, Xinjiang, PR China

关键词: Hypertrophy;    Endothelin-1;    Angiotensin-II;    2K1C experimental hypertension;    Dioscorea opposite Thunb;    Antihypertensive;   

Others  :  1220284
DOI  :  10.1186/1472-6882-14-36

 received in 2013-09-04, accepted in 2013-11-21,  发布年份 2014

【 摘 要 】

Background

Dioscorea opposita Thunb. (Huai Shan Yao, DOT), a common staple food in China, has been used for more than 2000 years in traditional Chinese medicine (TCM) to treat different systemic diseases including hypertension. The objective of this study was to investigate the possible antihypertensive effects of the aqueous extract of (DOT) in renovascular hypertensive rats as well as the mechanism in reducing blood pressure.

Methods

The two-kidney one-clip (2K1C) Goldblatt model of renovascular hypertension was used in Wistar rats. Rats with captopril, low-dose DOT and high-dose DOT treated 2K1C groups for 6 weeks. The blood pressure, cardiac mass index (heart weight/body weight), plasma level of angiotensin-II (Ang-II), endothelin-1(ET-1), superoxide dismutase (SOD) and malondialdehyde (MDA) were evaluated.

Results

DOT significantly reduced mean systolic and diastolic blood pressure after treatment. DOT also significantly increased plasma SOD activity but decreased plasma MDA concentration. Renal function was improved with captopril and DOT. DOT reduced plasma Ang-II activity and plasma ET concentration. They couldalso significantly reduce the left ventricular hypertrophy and cardiac mass index.

Conclusions

Our results suggest that DOT may have an antihypertensive effect on hypertension by inhibit ET-converting enzyme and antioxidant activity, which warrant further exploration.

【 授权许可】

   
2014 Amat et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Schutte A, Van Rooyen J, Huisman H, Krunger H, De Malan NT, Ridder JH: Dietary risk markers that contribute to the aetiology of hypertension in black South African childerens. The THUSA BAMMA study. J Hum Hypertens 2003, 17:29-35.
• [2]Guilbert JJ: The world health report: reducing risks, promoting healthy life. Educ Health (Abingdon) 2003, 16:230.
• [3]Arakawa K, Saruta T, Abe K, Iimura O, Ishii M, Ogihara T, Hiwada K, Fukiyama K, Fujishima M, Mizuno Y, Kikuchi T, Takaori S: Improvement of accessory symptoms of hypertension by TSUMURA Orengedokuto Extract, a four herbal drugs containing Kampo-Medicine Granules for ethical use: a double-blind, placebo-controlled study. Phytomed 2006, 13:1-10.
• [4]Herrera-Arellano A, Miranda-Sánchez J, Avila-Castro P, Herrera-Alvarez S, Jiménez-Ferrer JE, Zamilpa A, Román-Ramos R, Ponce-Monter H, Tortoriello J: Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med 2007, 73:6-12.
• [5]Sinitsyna O, Krysanova Z, Ishchenko A, Dikalova AE, Stolyarov S, Kolosova N, Vasunina E, Nevinsky G: Age-associated changes in oxidative damage and the activity of antioxidant enzymes in rats with inherited over generation of free radicals. J cell Mol Med 2006, 10:206-215.
• [6]Tahraoui A, El-Hilaly J, Israili ZH, Lyoussi B: Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-eastern Morocco (Errachidia province). J Ethnopharmacol 2007, 110:105-117.
• [7]Zuo YF, Tang DC: Science of Chinese Materia Medica. Shanghai, China: Shanghai University of Traditional Chinese Medicine Press; 2003:301-303.
• [8]Hsu HY, Chen YP, Hsu SJ, Chen JJ, Chang SC: Essentials of material medica. Taipei: New Medicine and Pharmacy press; 1984. In Chinese
• [9]Yen K: The illustrated Chinese materia medica. Taipei: SMC Publishing; 1992:84.
• [10]Bai B, Li MJ, Wang Y, Liu XH: Studies on chemical constituents of Dioscorea opposita. Zhongguo Zhong Yao Za Zhi 2008, 33:1272-1274. In Chinese
• [11]Fang YW, Zhao JJ, Ho YZ, Li BG, Xu CJ: Elucidation of the chemical structures of two steroid saponins of Dioscorea nippnica Makino. Acta Pharmaceutica Sinica 1972, 17:387-391. In Chinese
• [12]Wang T, Choi RC, Li J, Li J, Bi CW, Zang L, Liu Z, Dong TT, Bi K, Tsim KW: Antihyperlipidemic effect of protodioscin, an active ingredient isolated from the rhizomes of Dioscorea nipponica. Planta Med 2010, 76:1642-1646.
• [13]Liu H, Chou GX, Wu T, Guo YL, Wang SC, Wang CH, Wang ZT: Steroidal sapogenins and glycosides from the rhizomes of Dioscorea bulbifera. J Nat Prod 2009, 72:1964-1968.
• [14]Niu CS, Chen W, Wu HT, Cheng KC, Wen YJ, Lin KC, Cheng JT: Decrease of plasma glucose by allantoin, an active principle of yam (Dioscorea spp.), in streptozotocin-induced diabetic rats. J Agric Food Chem 2010, 58:12031-12035.
• [15]Ma HY, Zhao ZT, Wang LJ, Wang Y, Zhou QL, Wang BX: Comparative study on anti-hypercholesterolemia activity of diosgenin and total saponin of Dioscorea panthaica. Zhongguo zhongyao zazhi 2002, 27:528-531. In Chinese
• [16]Lee SC, Tsai CC, Chen JC, Lin JG, Lin CC, Hu ML, Lu S: Effects of Chinese yam on hepato-nephrotoxicity of acetaminophen in rats. Acta Pharmacol Sin 2002, 23:503-508.
• [17]Hou WC, Hsu FL, Lee MH: Yam (Dioscorea batatas) tuber mucilage exhibited antioxidant activities in vitro. Planta Med 2002, 68:1072-1076.
• [18]Liu YH, Lin YS, Liu DZ, Han CH, Chen CT, Fan M, Hou WC: Effects of different types of yam (Dioscorea alata) products on the blood pressure of spontaneously hypertensive rats. Bios Biotechnol Biochem 2009, 73:1371-1376.
• [19]Bidani AK, Griffin KA: Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004, 44:595-601.
• [20]Navar LG, Zou L, Von Thun A, Wang CT, Imig JD, Mitchell KD: Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 1998, 13:170-176.
• [21]Laragh JH: On the mechanisms and clinical relevance of one-kidney, one-clip hypertension. Am J Hypertens 1991, 4:541-545.
• [22]Pinto YM, Paul M, Ganten D: Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res 1998, 39:77-88.
• [23]Al-Qattan KK: Different levels of hypertension induce opposite diuretic behaviors from the nonclipped kidney in the rat two-kidney, one-clip model. Kidney Blood Press R 2001, 24:44-51.
• [24]Morishita R, Higaki J, Okunishi H, Nakamura F, Nagano M, Mikami H, Ishii K, Miyazaki M, Ogihara T: Role of tissue renin angiotensin system in two-kidney, one-clip hypertensive rats. Am J Physiol 1993, 264:510-514.
• [25]Carvalho MH, Fortes ZB, Nigro D, Oliveira MA, Scivoletto R: The role of thromboxane A2 in the altered microvascular reactivity in two-kidney, one clip hypertension. Endothelium 1997, 5:167-178.
• [26]Al-Qattan KK, Khan I, Alnaqeeb MA, Ali M: Thromboxane-B2, prostaglandin-E2 and hypertension in the rat 2-kidney 1-clip model: a possible mechanism of the garlic induced hypertension. Prostag Leukotr Ess 2001, 64:5-10.
• [27]Briones AM, Touyz RM: Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 2010, 12:135-142.
• [28]Haddad JJ: Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002, 14:879-897.
• [29]Ardanaz N, Pagano PJ: Hydrogen peroxide as a paracrine vascular mediator: regulation and signaling leading to dysfunction. Exp Biol Med 2006, 231:237-251.
• [30]Liochev SI, Fridovich I: The effects of superoxide dismutase on H2O2 formation. Free Radical Bio Med 2007, 42:1465-1469.
• [31]Umar A, Guzelnur I, Yimin Y, Kerim P, Tohti I, Berké B: Antihypertensive effects of Ocimum basilicum L. (OBL) on blood pressure in renovascular hypertensive rats. Hypertens Res 2010, 33:727-730.
• [32]Iversen BM, Heyeraas KJ, Sekse I, Andersen KJ, Ofstad J: Autoregulation of renal blood flow in two-kidney, one-clip hypertensive rats. Am J Physiol 1986, 25:245-250.
• [33]Iversen BM, Morkrid L, Ofstad J: Afferent arteriolar diameter in DOCA-salt and two-kidney one-clip hypertensive rats. Am J Physiol 1983, 245:755-762.
• [34]Ploth DW, Fitzgibbon W: Pathology of altered renal function in renal vascular hypertension. AJKD 1994, 24:652-659.
• [35]Rossi GP, Sacchetto A, Cesari M, Pessina AC: Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999, 43:300-307.
• [36]Gomez-Alamillo C, Juncos LA, Cases A, Haas JA, Romero JC: Interactions between vasoconstrictors and vasodilators in regulating hemodynamics of distinct vascular beds. Hypertension 2003, 42:831-836.
• [37]Sealey JE, Laragh JH: The renin-angiotensin-Aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In Hypertension: pathophysiology, diagnosis, and management. Volume 2. 2nd edition. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995. 17:63–179
• [38]Morris ST, Jardine AG: The vascular endothelium in chronic renal failure. J Nephrol 2000, 13:96-105.
• [39]Dumont Y, D’Amours M, Lebel M, Larivière R: Blood pressure-independent effects of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats. J Hypertens 2001, 19:1479-1487.
• [40]Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K: Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992, 20:292-297.
• [41]Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F: Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992, 19:753-757.
• [42]Crawford DC, Chobanian AV, Brecher P: Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994, 74:727-739.
• [43]Riggleman A, Harvey J, Baylis C: Endothelin mediates some of the renal actions of acutely administered angiotensin II. Hypertension 2001, 38:105-109.
• [44]Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, Kim HS, Smithies O, Le TH, Coffman TM: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006, 103:17985-1798590.
• [45]Cervenka L, Vanecková I, Husková Z, Vanourková Z, Erbanová M, Thumová M, Skaroupková P, Opocenský M, Malý J, Chábová VC, Tesar V, Bürgelová M, Viklický O, Teplan V, Zelízko M, Kramer HJ, Navar LG: Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor subtype 1A knockout mice. J Hypertens 2008, 26:1379-1389.
• [46]Forbes JM, Coughlan MT, Cooper ME: Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57:1446-1454.
• [47]Huang PL: eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrin Met 2009, 20:295-302.
• [48]Harrison DG, Gongora MC: Oxidative stress and hypertension. Med Clin North Am 2009, 93:621-635.
• [49]Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004, 44:248-252.
• [50]Ceriello A: Possible role of oxidative stress in the pathogenesis of hypertension. Diabetes Care 2008, 31:181-184.
• [51]Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT: Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003, 41:1096-1101.
• [52]Nabha L, Garbern JC, Buller CL, Charpie JR: Vascular oxidative stress precedes high blood pressure in spontaneously hypertensive rats. Clin Exp Hypertens 2005, 27:71-82.
• [53]Santina C, Giovanni C: Oxidative stress, inflammation and endothelial biomarkers in arterial hypertension. Curr Hypertens Rev 2008, 4:86-99.
• [54]Ward NC, Croft KD: Hypertension and oxidative stress. Clin Exp Pharmacol P 2006, 3:72-876.